EA201691027A1 - Модуляторы aplnr и их применение - Google Patents

Модуляторы aplnr и их применение

Info

Publication number
EA201691027A1
EA201691027A1 EA201691027A EA201691027A EA201691027A1 EA 201691027 A1 EA201691027 A1 EA 201691027A1 EA 201691027 A EA201691027 A EA 201691027A EA 201691027 A EA201691027 A EA 201691027A EA 201691027 A1 EA201691027 A1 EA 201691027A1
Authority
EA
Eurasian Patent Office
Prior art keywords
aplnr
diseases
modulators
antibodies
present
Prior art date
Application number
EA201691027A
Other languages
English (en)
Inventor
Панайотис Стевис
Джеспер Громада
Эндрю Дж. МЕРФИ
Йонетон Рэй
Дзее Х. Ким
Иван Б. Лобов
Original Assignee
Ридженерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52021453&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201691027(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ридженерон Фармасьютикалз, Инк. filed Critical Ридженерон Фармасьютикалз, Инк.
Publication of EA201691027A1 publication Critical patent/EA201691027A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

В настоящем изобретении предлагаются модуляторы апелинового рецептора (APLNR), которые связываются с APLNR, и способы их применения. Настоящее изобретение включает модуляторы APLNR, такие как антитела или их антигенсвязывающие фрагменты, которые ингибируют или ослабляют APLNR-опосредованную передачу сигнала. Настоящее изобретение включает модуляторы APLNR, такие как антитела или слитые с антителом белки, которые активируют APLNR-опосредованную передачу сигнала. Согласно некоторым вариантам реализации настоящего изобретения антитела или антигенсвязывающие фрагменты или слитые с антителом белки представляют собой полностью человеческие антитела, которые связываются с человеческим APLNR с высокой аффинностью. Модуляторы APLNR по настоящему изобретению пригодны для лечения заболеваний и патологий, ассоциированных с передачей сигнала APLNR и/или клеточной экспрессией APLNR, таких как сердечно-сосудистые заболевания, заболевания ангиогенеза, заболевания обмена веществ и фиброзные заболевания.
EA201691027A 2013-11-20 2014-11-20 Модуляторы aplnr и их применение EA201691027A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361906568P 2013-11-20 2013-11-20
PCT/US2014/066687 WO2015077491A1 (en) 2013-11-20 2014-11-20 Aplnr modulators and uses thereof

Publications (1)

Publication Number Publication Date
EA201691027A1 true EA201691027A1 (ru) 2016-12-30

Family

ID=52021453

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691027A EA201691027A1 (ru) 2013-11-20 2014-11-20 Модуляторы aplnr и их применение

Country Status (15)

Country Link
US (7) US10155811B2 (ru)
EP (1) EP3071600B1 (ru)
JP (2) JP6483117B2 (ru)
KR (1) KR20160086942A (ru)
CN (1) CN105916881A (ru)
AU (1) AU2014352962B2 (ru)
BR (1) BR112016011401A2 (ru)
CA (1) CA2931299C (ru)
CL (1) CL2016001212A1 (ru)
EA (1) EA201691027A1 (ru)
IL (1) IL245733A0 (ru)
MA (1) MA39061A1 (ru)
MX (1) MX2016006709A (ru)
PH (1) PH12016500943A1 (ru)
WO (1) WO2015077491A1 (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140093496A1 (en) 2011-02-25 2014-04-03 Chugai Seiyaku Kabushiki Kaisha Fc-gamma-RIIb-SPECIFIC Fc ANTIBODY
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
US20150056182A1 (en) 2011-11-30 2015-02-26 Chugai Seiyaku Kabushiki Kaisha Drug containing carrier into cell for forming immune complex
TWI717591B (zh) 2012-08-24 2021-02-01 日商中外製藥股份有限公司 ＦｃγＲＩＩｂ特異性Ｆｃ區域變異體
ES2876009T3 (es) 2012-12-27 2021-11-11 Chugai Pharmaceutical Co Ltd Polipéptido heterodimerizado
BR112015020587A2 (pt) 2013-03-14 2017-10-10 Regeneron Pharma proteínas de fusão de apelina e suas utilizações
CA2908350C (en) 2013-04-02 2023-08-08 Futa Mimoto Fc region variant
US11104730B2 (en) 2013-11-20 2021-08-31 Regeneren Pharmaceuticals, Inc. Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors
BR112016011401A2 (pt) 2013-11-20 2017-09-26 Regeneron Pharma moduladores de aplnr e utilizações dos mesmos
MA41294A (fr) 2014-12-19 2017-11-08 Chugai Pharmaceutical Co Ltd Anticorps anti-myostatine, polypeptides contenant des variants de régions fc, et procédés d'utilisation
WO2016125495A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
AU2016332725A1 (en) * 2015-09-29 2018-03-22 Celgene Corporation PD-1 binding proteins and methods of use thereof
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
EP3228630A1 (en) 2016-04-07 2017-10-11 IMBA-Institut für Molekulare Biotechnologie GmbH Combination of an apelin antagonist and an angiogenesis inhibitor for the treatment of cancer
RU2766112C2 (ru) 2016-08-05 2022-02-08 Чугаи Сейяку Кабусики Кайся Композиция для профилактики или лечения связанных с il-8 заболеваний
US10766958B2 (en) 2016-09-19 2020-09-08 Celgene Corporation Methods of treating vitiligo using PD-1 binding antibodies
KR102257154B1 (ko) 2016-09-19 2021-05-28 셀진 코포레이션 Pd-1 결합 단백질을 사용하는 면역 질환의 치료 방법
WO2018208625A1 (en) 2017-05-06 2018-11-15 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with aplnr antagonists and vegf inhibitors
CN110655577A (zh) * 2018-06-13 2020-01-07 鸿运华宁（杭州）生物医药有限公司 APJ抗体及其与Elabela的融合蛋白质，以及其药物组合物和应用
WO2020257460A2 (en) * 2019-06-19 2020-12-24 Ab Initio Biotherapeutics, Inc. Apj modulators and uses thereof
GB202015755D0 (en) * 2020-10-05 2020-11-18 Rogers Arpi Coronavirus therapy

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2148299B (en) 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
WO1999033976A1 (en) 1997-12-24 1999-07-08 Takeda Chemical Industries, Ltd. Polypeptide, their production and use
US6475718B2 (en) 1998-09-08 2002-11-05 Schering Aktiengesellschaft Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus
BR0013231A (pt) * 1999-08-09 2002-07-23 Lexigen Pharm Corp Complexos citocina-anticorpo múltiplos
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
WO2002036762A1 (fr) 2000-10-30 2002-05-10 Takeda Chemical Industries, Ltd. Procede de fabrication de peptides
US7119185B2 (en) 2000-12-21 2006-10-10 Trustees Of The University Of Pennsylvania Hormonally up-regulated, neu-tumor-associated kinase
DE10138569A1 (de) 2001-08-06 2003-04-30 Bayer Ag Regulation des APJ-Rezeptors
EP1613348B1 (en) 2003-03-12 2010-06-23 The Arizona Board of Regents on Behalf of the University of Arizona Methods for modulating angiogenesis with apelin compositions
CN1926237A (zh) 2004-01-28 2007-03-07 森托尼克斯制药有限公司 用于治疗不育症的异二聚体促卵泡激素－Fc(FSH－Fc)融合蛋白
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
WO2005106493A1 (en) * 2004-04-30 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled apelin receptor (apj)
WO2006023893A2 (en) 2004-08-23 2006-03-02 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for modulating angiogenesis and apoptosis with apelin compositions
WO2006076736A2 (en) 2005-01-14 2006-07-20 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for modulating angiogenesis, lymphangiogenesis, and apoptosis with apelin compositions
AU2006280004A1 (en) 2005-08-12 2007-02-22 Schering Corporation MCP1 fusions
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
CA2634363A1 (en) 2005-12-20 2007-06-28 Takeda Pharmaceutical Company Limited Novel application of apelin
SI2041177T1 (sl) 2006-06-02 2012-03-30 Regeneron Pharma Visoko afinitetna protitelesa za humani IL receptor
WO2008081198A1 (en) 2007-01-05 2008-07-10 Imperial Innovations Ltd Blood assays for predicting inflammatory responses
DK2662449T3 (en) 2007-05-30 2017-05-15 Postech Academy-Industry- Found immunoglobulin fusion proteins
CA2742528A1 (en) 2008-11-04 2010-05-14 Anchor Therapeutics, Inc. Apj receptor compounds
EP2401298A1 (en) 2009-02-24 2012-01-04 Glaxo Group Limited Antigen-binding constructs
US8946382B2 (en) 2009-02-27 2015-02-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Apelin peptides and methods of use
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
CN106399276B (zh) 2009-11-02 2021-08-10 华盛顿大学 治疗性核酸酶组合物和方法
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
CN105585630B (zh) 2010-07-29 2020-09-15 Xencor公司 具有修改的等电点的抗体
AU2012229336B2 (en) 2011-03-11 2017-02-02 Genzyme Corporation Pegylated Apelin and uses thereof
CN103458910A (zh) 2011-03-31 2013-12-18 株式会社资生堂 潮热抑制剂
WO2013012855A1 (en) 2011-07-18 2013-01-24 Amgen Inc. Apelin antigen-binding proteins and uses thereof
US9381229B2 (en) 2011-11-28 2016-07-05 Inserm (Institut National De La Sante Et De La Recherche Medicale) Pharmaceutical composition for use in the treatment of dysfunction associated with aging
CN102516393B (zh) 2011-11-30 2017-03-15 北京康明百奥新药研发有限公司 胰岛素模拟肽融合蛋白和突变体及其应用
MX361875B (es) 2012-03-14 2018-12-18 Regeneron Pharma Moléculas de unión de antígeno multiespecifícas y usos de las mismas.
US20160067347A1 (en) 2012-12-20 2016-03-10 Amgen Inc. Apj receptor agonists and uses thereof
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
BR112015020587A2 (pt) 2013-03-14 2017-10-10 Regeneron Pharma proteínas de fusão de apelina e suas utilizações
MX2016001021A (es) 2013-07-25 2016-08-03 Novartis Ag Bioconjugados de polipeptidos de apelina sinteticos.
BR112016011401A2 (pt) 2013-11-20 2017-09-26 Regeneron Pharma moduladores de aplnr e utilizações dos mesmos

Also Published As

Publication number Publication date
JP2019094343A (ja) 2019-06-20
MA39061A1 (fr) 2017-10-31
JP2017500018A (ja) 2017-01-05
US10189901B2 (en) 2019-01-29
US10947310B2 (en) 2021-03-16
CA2931299C (en) 2024-03-05
EP3071600A1 (en) 2016-09-28
MX2016006709A (es) 2016-09-08
AU2014352962B2 (en) 2019-11-07
KR20160086942A (ko) 2016-07-20
PH12016500943A1 (en) 2016-06-27
US11642390B2 (en) 2023-05-09
US10626173B2 (en) 2020-04-21
US20170058028A1 (en) 2017-03-02
CL2016001212A1 (es) 2016-12-09
WO2015077491A1 (en) 2015-05-28
US20170210800A1 (en) 2017-07-27
US20240091301A1 (en) 2024-03-21
US9644018B2 (en) 2017-05-09
BR112016011401A2 (pt) 2017-09-26
US20190048074A1 (en) 2019-02-14
IL245733A0 (en) 2016-07-31
CN105916881A (zh) 2016-08-31
JP6483117B2 (ja) 2019-03-13
US20210403551A1 (en) 2021-12-30
JP6738449B2 (ja) 2020-08-12
US10155811B2 (en) 2018-12-18
US20190177410A1 (en) 2019-06-13
US20150252107A1 (en) 2015-09-10
CA2931299A1 (en) 2015-05-28
EP3071600B1 (en) 2020-06-17
AU2014352962A1 (en) 2016-06-23

Similar Documents

Publication Publication Date Title
EA201691027A1 (ru) Модуляторы aplnr и их применение
UA118029C2 (uk) Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
EA201591716A1 (ru) Антитела анти-il-33 и их применение
EA201591072A1 (ru) Антитела против pdgfr-бета и их применения
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
EA201792221A1 (ru) Антитела против сортилина и способы их применения
PH12014502527A1 (en) St2 antigen binding proteins
EA201492101A1 (ru) Антитела против fcrn
TR201809571T4 (tr) Ll-22 polipeptidleri ile ıl-22 fc füzyon proteinleri ve kullanım yöntemleri.
EA202191380A1 (ru) Антитела к альфа-синуклеину и их применение
EA201890928A1 (ru) Антигенсвязывающие белки, которые активируют лептиновый рецептор
EA201792193A1 (ru) Конструкции биспецифического антитела для cdh3 и cd3
MA34004B1 (fr) Protéines de liaison à cd127
PH12015500480A1 (en) Antibody formulations and uses thereof
EA201591974A1 (ru) Антитела человека, связывающиеся с g-белком rsv
EA201792466A1 (ru) АНТИТЕЛА ПРОТИВ FcRn
EA201992206A1 (ru) Моноклональное антитело к pd-l1
EA201690503A1 (ru) Антитела
EA201690992A1 (ru) Антитела, специфичные к fcrn
EA201892440A1 (ru) Антитела к tl1a и их применения
EA201591993A1 (ru) Лечение склеродермии с применением комбинированной терапии антителами анти-ccl2 и анти-loxl2
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
EA201590918A1 (ru) Антитела к bmp-6
EA201591898A1 (ru) Антитела, направленные на m-csf